Skip to main content
Explore URMC
menu

CBRS18119 / S1706 / Ajay Dhakal

Research Question:
How well does radiation therapy with or without olaparib work in treating patients with inflammatory breast cancer?

Basic Study Information

Purpose:
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.

Location: University of Rochester Medical Center
Study Reference #: CBRS18119

Lead Researcher (Principal Investigator)

Lead Researcher:  Ajay Dhakal

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search